Literature DB >> 21946431

Functional significance of glycogen synthase kinase-3 regulation by serotonin.

Abigail M Polter1, Sufen Yang, Richard S Jope, Xiaohua Li.   

Abstract

Serotonin modulates brain physiology and behavior and has major roles in brain diseases involving abnormal mood and cognition. Enhancing brain serotonin has been found to regulate glycogen synthase Kinase-3 (GSK3), but the signaling mechanism and functional significance of this regulation remain to be determined. In this study, we tested the signaling mechanism mediating 5-HT1A receptor-regulated GSK3 in the hippocampus. Using mutant GSK3 knock-in mice, we also tested the role of GSK3 in the behavioral effects of 5-HT1A receptors and the serotonin reuptake inhibitor fluoxetine. The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3α and GSK3β in several areas of the hippocampus. The effect of 8-OH-DPAT was accompanied by an increase in the active phosphorylation of Akt, and was blocked by LY294002, an inhibitor of phosphoinositide 3-kinases (PI3K). Phosphorylation of GSK3β, but not GSK3α, was necessary for 5-HT1A receptors to suppress the hippocampus-associated contextual fear learning. Furthermore, acute fluoxetine treatment up-regulated both phospho-Ser21-GSK3α and phospho-Ser9-GSK3β in the hippocampus. Blocking phosphorylation of GSK3α and GSK3β diminished the anti-immobility effect of fluoxetine treatment in the forced swim test, wherein the effect of GSK3β was more prominent. These results together suggest that PI3K/Akt is a signaling mechanism mediating the GSK3-regulating effect of 5-HT1A receptors in the hippocampus, and regulation of GSK3 is an important intermediate signaling process in the behavioral functions of 5-HT1A receptors and fluoxetine.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946431      PMCID: PMC3205250          DOI: 10.1016/j.cellsig.2011.09.009

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  45 in total

1.  Roles of extracellular signal-regulated kinase and Akt signaling in coordinating nuclear transcription factor-kappaB-dependent cell survival after serotonin 1A receptor activation.

Authors:  Shu-chi Hsiung; Hadassah Tamir; Thomas F Franke; Kuo-peing Liu
Journal:  J Neurochem       Date:  2005-10-20       Impact factor: 5.372

Review 2.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

Authors:  Eléonore Beurel; Richard S Jope
Journal:  Prog Neurobiol       Date:  2006-08-28       Impact factor: 11.685

3.  Reliability assessment of an automated forced swim test device using two mouse strains.

Authors:  Murat Kurtuncu; Lance J Luka; Nikola Dimitrijevic; Tolga Uz; Hari Manev
Journal:  J Neurosci Methods       Date:  2005-06-20       Impact factor: 2.390

4.  Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.

Authors:  Edward J McManus; Kei Sakamoto; Laura J Armit; Leah Ronaldson; Natalia Shpiro; Rodolfo Marquez; Dario R Alessi
Journal:  EMBO J       Date:  2005-03-24       Impact factor: 11.598

5.  Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics.

Authors:  Xiaohua Li; Kelley M Rosborough; Ari B Friedman; Wawa Zhu; Kevin A Roth
Journal:  Int J Neuropsychopharmacol       Date:  2006-05-04       Impact factor: 5.176

6.  5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons.

Authors:  Daniel S Cowen; Nadine N Johnson-Farley; Tatyana Travkina
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

7.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

8.  Adaptive changes in 5-HT1A receptor-mediated hippocampal inhibition in the alert rat produced by repeated 8-OH-DPAT treatment.

Authors:  D Manahan-Vaughan; R Anwyl; M J Rowan
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

9.  LTP inhibits LTD in the hippocampus via regulation of GSK3beta.

Authors:  Stéphane Peineau; Changiz Taghibiglou; Clarrisa Bradley; Tak Pan Wong; Lidong Liu; Jie Lu; Edmond Lo; Dongchuan Wu; Emilia Saule; Tristan Bouschet; Paul Matthews; John T R Isaac; Zuner A Bortolotto; Yu Tian Wang; Graham L Collingridge
Journal:  Neuron       Date:  2007-03-01       Impact factor: 17.173

10.  Glycogen synthase kinase-3 inhibition is integral to long-term potentiation.

Authors:  Claudie Hooper; Vladimir Markevich; Florian Plattner; Richard Killick; Emma Schofield; Tobias Engel; Felix Hernandez; Brian Anderton; Kobi Rosenblum; Tim Bliss; Sam F Cooke; Jesús Avila; José J Lucas; Karl Peter Giese; John Stephenson; Simon Lovestone
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

View more
  33 in total

1.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

2.  The fibroblast growth factor 14·voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3).

Authors:  Alexander S Shavkunov; Norelle C Wildburger; Miroslav N Nenov; Thomas F James; Tetyana P Buzhdygan; Neli I Panova-Elektronova; Thomas A Green; Ronald L Veselenak; Nigel Bourne; Fernanda Laezza
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

3.  Fluoxetine Inhibits Natural Decay of Long-Term Memory via Akt/GSK-3β Signaling.

Authors:  Jee Hyun Yi; JiaBao Zhang; Sang Yoon Ko; Huiyoung Kwon; Se Jin Jeon; Se Jin Park; Jiwook Jung; Byung C Kim; Young Choon Lee; Dong Hyun Kim; Jong Hoon Ryu
Journal:  Mol Neurobiol       Date:  2018-02-09       Impact factor: 5.590

Review 4.  Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs.

Authors:  Jeffrey L Barr; Ellen M Unterwald
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-05-23       Impact factor: 4.739

5.  Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats.

Authors:  Peng Liu; Li-Bo Zou; Li-Hua Wang; Qing Jiao; Tian-Yan Chi; Xue-Fei Ji; Ge Jin
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

6.  Linoleic acid derivative DCP-LA ameliorates stress-induced depression-related behavior by promoting cell surface 5-HT1A receptor translocation, stimulating serotonin release, and inactivating GSK-3β.

Authors:  Takeshi Kanno; Akito Tanaka; Tomoyuki Nishizaki
Journal:  Mol Neurobiol       Date:  2014-05-01       Impact factor: 5.590

7.  Exposure to serotonin adversely affects oligodendrocyte development and myelination in vitro.

Authors:  Lir-Wan Fan; Abhay Bhatt; Lu-Tai Tien; Baoying Zheng; Kimberly L Simpson; Rick C S Lin; Zhengwei Cai; Praveen Kumar; Yi Pang
Journal:  J Neurochem       Date:  2015-01-28       Impact factor: 5.372

Review 8.  Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.

Authors:  Olivia O'Leary; Yvonne Nolan
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 9.  Rethinking 5-HT1A receptors: emerging modes of inhibitory feedback of relevance to emotion-related behavior.

Authors:  Stefanie C Altieri; Alvaro L Garcia-Garcia; E David Leonardo; Anne M Andrews
Journal:  ACS Chem Neurosci       Date:  2012-12-20       Impact factor: 4.418

10.  Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT.

Authors:  Tomohisa Mori; Naoki Uzawa; Yoshiyuki Iwase; Daiki Masukawa; Mahardian Rahmadi; Shigeto Hirayama; Mayuna Hokazono; Kimio Higashiyama; Seiji Shioda; Tsutomu Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2016-04-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.